Clinical Trials Logo

Central Nervous System Neoplasms clinical trials

View clinical trials related to Central Nervous System Neoplasms.

Filter by:

NCT ID: NCT00006342 Completed - Lymphoma Clinical Trials

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

Start date: January 1997
Phase: N/A
Study type: Observational

RATIONALE: Determination of genetic markers for leukemia or non-Hodgkin's lymphoma that is secondary to Hodgkin's disease and childhood brain tumors may help doctors to identify patients who are at risk for these cancers. PURPOSE: Clinical trial to determine the presence of certain genes in patients who are receiving treatment for Hodgkin's disease or childhood brain tumors.

NCT ID: NCT00006268 Completed - Clinical trials for Brain and Central Nervous System Tumors

Immunotoxin Therapy in Treating Patients With Malignant Glioma

Start date: October 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for malignant glioma. PURPOSE: Phase I/II trial to study the effectiveness of immunotoxin therapy in treating patients who have malignant glioma.

NCT ID: NCT00006258 Completed - Clinical trials for Brain and Central Nervous System Tumors

Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Start date: November 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by radiation therapy in treating patients who have surgically resected, newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor, or incompletely resected ependymoma.

NCT ID: NCT00006246 Completed - Lymphoma Clinical Trials

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

Start date: November 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who have refractory CNS cancer and to estimate the maximum tolerated dose of this treatment regimen.

NCT ID: NCT00006119 Completed - Clinical trials for Brain and Central Nervous System Tumors

Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

Start date: July 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.

NCT ID: NCT00006102 Completed - Lymphoma Clinical Trials

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

Start date: July 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

NCT ID: NCT00006093 Completed - Clinical trials for Brain and Central Nervous System Tumors

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

Start date: September 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.

NCT ID: NCT00006080 Completed - Clinical trials for Brain and Central Nervous System Tumors

Fenretinide in Treating Patients With Recurrent Malignant Glioma

Start date: September 25, 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent malignant glioma.

NCT ID: NCT00006025 Completed - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

Start date: January 5, 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.

NCT ID: NCT00006024 Completed - Brain Tumor Clinical Trials

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

Start date: November 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of temozolomide plus lomustine followed by radiation therapy in treating patients who have high-grade malignant glioma.